Contents

Current Pharmaceutical Biotechnology, Volume 7 - Number 3

Editorial [ Proteomic Technologies in Translational MedicineGuest Editor: Frode Selheim ]

, 7(3): 133

Frode Selheim


DOI: 10.2174/138920106777549740




Proteomic and Computational Methods in Systems Modeling of Cellular Signaling

, 7(3): 135 - 145

R. Kleppe, E. Kjarland and F. Selheim


DOI: 10.2174/138920106777549722




Proteomic-Based Biomarker Discovery with Emphasis on Cerebrospinal Fluid and Multiple Sclerosis

, 7(3): 147 - 158

F. S. Berven, K. Flikka, M. Berle, C. Vedeler and R. J. Ulvik


DOI: 10.2174/138920106777549713




Proteomic Strategies for Individualizing Therapy of Acute MyeloidLeukemia (AML)

, 7(3): 159 - 170

Gry Sjoholt, Siv Lise Bedringaas, Anne P. Doskeland and Bjorn Tore Gjertse


DOI: 10.2174/138920106777549759




Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias

, 7(3): 171 - 183

Laure Deville, Josette Hillion, Michel Lanotte, Philippe Rousselot and Evelyne Segal-Bendirdjian


DOI: 10.2174/138920106777549768




Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies

, 7(3): 185 - 198

Eystein Oveland, Kari E. Fladmark, Line Wergeland, Bjorn Tore Gjertsen and Randi Hovland


DOI: 10.2174/138920106777549696




Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia

, 7(3): 199 - 207

Nina Anensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle and Bjorn Tore Gjertsen


DOI: 10.2174/138920106777549731




Algal Toxins as Guidance to Identify Phosphoproteins with Key Roles inApoptotic Cell Death

, 7(3): 209 - 215

T. Solstad and K. E. Fladmark


DOI: 10.2174/138920106777549704




Does Isoform Diversity Explain Functional Differences in the 14-3-3Protein Family?

, 7(3): 217 - 223

E. Kjarland, T. J. Keen and R. Kleppe


DOI: 10.2174/138920106777549777




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science